Goldman Sachs
KALV

Goldman Sachs’s KalVista Pharmaceuticals KALV Stock Holding History

Goldman Sachs’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.6M Sell
824,293
-11,011
-1% -$177K ﹤0.01% 2614
2025
Q4 		$13.5M Sell
835,304
-964,877
-54% -$12.8M ﹤0.01% 2772
2025
Q3 		$21.9M Buy
1,800,181
+1,665,783
+1,239% +$23M ﹤0.01% 2166
2025
Q2 		$1.52M Sell
134,398
-205,538
-60% -$2.51M ﹤0.01% 4388
2025
Q1 		$3.92M Buy
339,936
+12,263
+4% +$125K ﹤0.01% 3590
2024
Q4 		$2.78M Buy
327,673
+193,632
+144% +$2.01M ﹤0.01% 4011
2024
Q3 		$1.55M Sell
134,041
-78,847
-37% -$992K ﹤0.01% 4360
2024
Q2 		$2.51M Buy
212,888
+153,057
+256% +$1.79M ﹤0.01% 3754
2024
Q1 		$710K Sell
59,831
-27,268
-31% -$364K ﹤0.01% 4557
2023
Q4 		$1.07M Sell
87,099
-121,713
-58% -$1.11M ﹤0.01% 4350
2023
Q3 		$2.01M Sell
208,812
-84,499
-29% -$863K ﹤0.01% 3768
2023
Q2 		$2.64M Buy
293,311
+17,827
+6% +$164K ﹤0.01% 3655
2023
Q1 		$2.17M Sell
275,484
-70,221
-20% -$524K ﹤0.01% 3795
2022
Q4 		$2.34M Buy
345,705
+7,525
+2% +$40.3K ﹤0.01% 3824
2022
Q3 		$4.91M Buy
338,180
+36,905
+12% +$516K ﹤0.01% 3153
2022
Q2 		$2.96M Buy
301,275
+134,570
+81% +$1.48M ﹤0.01% 3684
2022
Q1 		$2.46M Buy
166,705
+67,274
+68% +$967K ﹤0.01% 4062
2021
Q4 		$1.31M Buy
99,431
+30,136
+43% +$480K ﹤0.01% 4615
2021
Q3 		$1.21M Buy
69,295
+37,685
+119% +$764K ﹤0.01% 4603
2021
Q2 		$757K Sell
31,610
-22,989
-42% -$601K ﹤0.01% 4960
2021
Q1 		$1.4M Buy
54,599
+44,029
+417% +$1.16M ﹤0.01% 4334
2020
Q4 		$201K Buy
+10,570
New +$181K ﹤0.01% 5088
2020
Q3 		– Sell
-36,781
Closed -$445K – 5437
2020
Q2 		$445K Buy
+36,781
New +$391K ﹤0.01% 4439
2020
Q1 		– Sell
-20,213
Closed -$360K – 5391
2019
Q4 		$360K Sell
20,213
-26,881
-57% -$351K ﹤0.01% 4672
2019
Q3 		$546K Buy
47,094
+26,181
+125% +$423K ﹤0.01% 4406
2019
Q2 		$463K Sell
20,913
-16,877
-45% -$396K ﹤0.01% 4432
2019
Q1 		$1.08M Buy
+37,790
New +$819K ﹤0.01% 4012
2018
Q1 		– Sell
-15,528
Closed -$151K – 6157
2017
Q4 		$151K Buy
+15,528
New +$162K ﹤0.01% 5556
2016
Q4 		– Sell
-6,820
Closed -$44K – 6986
2016
Q3 		$44K Sell
6,820
-5
-0.1% -$38 ﹤0.01% 6517
2016
Q2 		$63K Sell
6,825
-34,994
-84% -$405K ﹤0.01% 6332
2016
Q1 		$377K Buy
41,819
+35,332
+545% +$633K ﹤0.01% 5036
2015
Q4 		$329K Sell
6,487
-3,490
-35% -$183K ﹤0.01% 5276
2015
Q3 		$499K Sell
9,977
-2,095
-17% -$179K ﹤0.01% 5137
2015
Q2 		$1.21M Buy
+12,072
New +$1.2M ﹤0.01% 4362

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs's KALV Position: Q1 2026 in Review

Goldman Sachs reduced its KalVista Pharmaceuticals (KALV) stake by 1.3% in Q1 2026, selling an estimated $177K and leaving 824,293 shares worth $16.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2614.

Goldman Sachs first reported a position in KALV in Q2 2015 and has held it in 34 quarters since. The position peaked at $21.9M in Q3 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Goldman Sachs held 824,293 shares of KalVista Pharmaceuticals worth $16.6M as of Q1 2026.
  • Goldman Sachs sold 11,011 KalVista Pharmaceuticals shares in Q1 2026, an estimated $177K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2614 holding.
  • Goldman Sachs first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 34 quarters since.
  • Goldman Sachs's KalVista Pharmaceuticals position peaked at $21.9M in Q3 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.